Labetuzumab I-131

N/A

Report date: 2025/09/11 14:20:57

Base Information

Drug NameLabetuzumab I-131
Drug Alias NameHumanised anti-CEA monoclonal antibody MN 14-I-131Anti-CEA monoclonal antibody MN 14-I-131131I-labetuzumabCEA-Cide-I-131hAFP-Y-90 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Nuclides > Iodine > 131IRadiation-emitting products > Radioactive therapeutic agent +[4] 
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 antagonistsIonising radiation emitters
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsLung NeoplasmsOvarian NeoplasmsRectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunomedics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences IncCenter For Molecular Medicine And Immunology Inc
Active IndicationsN/A
Inactive IndicationsLung NeoplasmsOvarian NeoplasmsRectal Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A